Onbone Oy raises €10m from international investor syndicate

Onbone Oy, the developer of novel casting technology material, Woodcast®, has raised a total of €10 million in a financing round led by MVM Life Science Partners. The funding round will be used to finance the international launch of the Woodcast suite of casting and splinting products.

Onbone’s innovative technology improves the clinical care of patients whilst reducing cost for hospitals and lowering the environmental impact of current technologies. The product suite is ecological, user-friendly and applicable for all orthopaedic and traumatology uses.

Woodcast is manufactured from wood and biodegradable plastic making it completely non-toxic and a perfectly mouldable and remouldable composite material suitable for all casting and splinting work. It can be used without water or rubber gloves. Patients can be imaged without removing Woodcast, which saves time and expense during patient follow-up. Woodcast has already been launched in several EU territories, with >30,000 patients successfully treated. This funding round will enable the business to expand to the wider global market.

As a part of the financing round Stuart Ashman will join the company as CEO. Stuart has a 20 year career in the casting market, being Director of Sales and Marketing at the market leading BSN Medical and more recently President of Andover Medical.

“We are pleased with this support from our new as well as existing investors. Their combined experience and financial backing will enable us to build a top quality international sales and marketing organisation. I feel that this patent protected technology has the features set to achieve a significant share of the cast product market in the big five EU countries and the United States”, comments Stuart.

“MVM is excited to bring new CEO Stuart Ashman, a senior executive in the casting and splinting market to the business. We believe Onbone’s novel technology can revolutionise fracture/injury management, improving patient outcomes in a cost efficient manner”, said Bali Muralidhar, M.D., Ph.D., partner at MVM who will join the Onbone Board of Directors.

“We look forward to supporting the business with Finnish Industry Investment and Inveni Capital to make it a global success and expect to announce further hires to the senior management team over the coming quarters.”

Onbone Oy

Onbone Oy
Medical Devices



DownloadPress Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.